Abstract
Purpose
Ischemia-reperfusion injury leads to impaired smooth muscle function and inflammatory reactions after intestinal transplantation. In previous studies, infliximab has been shown to effectively protect allogenic intestinal grafts in the early phase after transplantation with resulting improved contractility. This study was designed to reveal protective effects of infliximab on ischemia–reperfusion injury in isogenic transplantation.
Methods
Isogenic, orthotopic small bowel transplantation was performed in Lewis rats (3 h cold ischemia). Five groups were defined: non-transplanted animals with no treatment (group 1), isogenic transplanted animals with vehicle treatment (groups 2/3) or with infliximab treatment (5 mg/kg body weight intravenously, directly after reperfusion; groups 4/5). The treated animals were sacrificed after 3 (group 2/4) or 24 h (group 3/5). Histological and immunohistochemical analysis, TUNEL staining, real-time RT-PCR, and contractility measurements in a standard organ bath were used for determination of ischemia–reperfusion injury.
Results
All transplanted animals showed reduced smooth muscle function, while no significant advantage of infliximab treatment was observed. Reduced infiltration of neutrophils was noted in the early phase in animals treated with infliximab. The structural integrity of the bowel and infiltration of ED1-positive monocytes and macrophages did not improve with infliximab treatment. At 3 h after reperfusion, mRNA expression of interleukin (IL)-6, TNF-α, IL-10, and iNOS and MCP-1 displayed increased activation in the infliximab group.
Conclusion
The protective effects of infliximab in the early phase after experimental small bowel transplantation seem to be unrelated to ischemia–reperfusion injury. The promising effects in allogenic transplantation indicate the need for further experiments with infliximab as complementary treatment under standard immunosuppressive therapy. Further experiments should focus on additional infliximab treatment in the setting of acute rejection.
Similar content being viewed by others
References
Ueno T, Fukuzawa M (2010) Current status of intestinal transplantation. Surg Today 40(12):1112–1122
Abu-Elmagd KM, Costa G, Bond GJ, Soltys K, Sindhi R, Wu T et al (2009) Five hundred intestinal and multivisceral transplantations at a single center: major advances with new challenges. Ann Surg 250(4):567–581
Fishbein T, Novitskiy G, Mishra L, Matsumoto C, Kaufman S, Goyal S et al (2008) NOD2-expressing bone marrow-derived cells appear to regulate epithelial innate immunity of the transplanted human small intestine. Gut 57(3):323–330
Pascher A, Klupp J, Langrehr JM, Neuhaus P (2005) Anti-TNF-alpha therapy for acute rejection in intestinal transplantation. Transplant Proc 37(3):1635–1636
Pascher A, Radke C, Dignass A, Schulz RJ, Veltzke-Schlieker W, Adler A et al (2003) Successful infliximab treatment of steroid and OKT3 refractory acute cellular rejection in two patients after intestinal transplantation. Transplantation 76(3):615–618
Pirenne J, Kawai M (2009) Intestinal transplantation: evolution in immunosuppression protocols. Curr Opin Organ Transplant 14(3):250–255
Gerlach UA, Koch M, Muller HP, Veltzke-Schlieker W, Neuhaus P, Pascher A (2011) Tumor necrosis factor alpha inhibitors as immunomodulatory antirejection agents after intestinal transplantation. Am J Transplant 11(5):1041–1050
Pascher A, Klupp J (2005) Biologics in the treatment of transplant rejection and ischemia/reperfusion injury: new applications for TNFalpha inhibitors? BioDrugs 19(4):211–231
Schaefer N, Tahara K, Schmidt J, Zobel S, Kalff JC, Hirner A et al (2006) Mechanism and impact of organ harvesting and ischemia-reperfusion injury within the graft muscularis in rat small bowel transplantation. Transplant Proc 38(6):1821–1822
Schaefer N, Tahara K, Schuchtrup S, Websky MV, Overhaus M, Schmidt J et al (2008) Perioperative glycine treatment attenuates ischemia/reperfusion injury and ameliorates smooth muscle dysfunction in intestinal transplantation. Transplantation 85(9):1300–1310
Hummel M, Kurian SM, Lin S, Borodyanskiy A, Zhang Z, Li Z et al (2009) Intragraft TNF receptor signaling contributes to activation of innate and adaptive immunity in a renal allograft model. Transplantation 87(2):178–188
Pech T, Finger T, Fujishiro J, Praktiknjo M, Ohsawa I, Abu-Elmagd K et al (2010) Perioperative infliximab application ameliorates acute rejection associated inflammation after intestinal transplantation. Am J Transplant 10(11):2431–2441
Schwarz NT, Nakao A, Nalesnik MA, Kalff JC, Murase N, Bauer AJ (2002) Protective effects of ex vivo graft radiation and tacrolimus on syngeneic transplanted rat small bowel motility. Surgery 131(4):413–423
Park PO, Haglund U, Bulkley GB, Falt K (1990) The sequence of development of intestinal tissue injury after strangulation ischemia and reperfusion. Surgery 107(5):574–580
Park PO, Wallander J, Tufveson G, Haglund U (1991) Cold ischemic and reperfusion injury in a model of small bowel transplantation in the rat. Eur Surg Res 23(1):1–8
Kalff JC, Schraut WH, Simmons RL, Bauer AJ (1998) Surgical manipulation of the gut elicits an intestinal muscularis inflammatory response resulting in postsurgical ileus. Ann Surg 228(5):652–663
Türler A, Moore BA, Pezzone MA, Overhaus M, Kalff JC, Bauer AJ (2002) Colonic postoperative inflammatory ileus in the rat. Ann Surg 236:56–66
Schaefer N, Tahara K, Schmidt J, Wehner S, Kalff JC, Abu-Elmagd K et al (2007) Resident macrophages are involved in intestinal transplantation-associated inflammation and motoric dysfunction of the graft muscularis. Am J Transplant 7(5):1062–1070
Schaefer N, Tahara K, Von Websky M, Wehner S, Pech T, Tolba R et al (2008) Role of resident macrophages in the immunologic response and smooth muscle dysfunction during acute allograft rejection after intestinal transplantation. Transpl Int 21(8):778–791
Schaefer N, Tahara K, Websky MV, Koscielny A, Pantelis D, Kalff JC et al (2008) Acute rejection and the muscularis propria after intestinal transplantation: the alloresponse, inflammation, and smooth muscle function. Transplantation 85(10):1465–1475
Schmittgen TD, Zakrajsek BA, Mills AG, Gorn V, Singer MJ, Reed MW (2000) Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. Anal Biochem 285(2):194–204
Vollmar B, Menger MD (2011) Intestinal ischemia/reperfusion: microcirculatory pathology and functional consequences. Langenbecks Arch Surg 396(1):13–29
Arumugam TV, Okun E, Tang SC, Thundyil J, Taylor SM, Woodruff TM (2009) Toll-like receptors in ischemia-reperfusion injury. Shock 32(1):4–16
Land WG (2005) The role of postischemic reperfusion injury and other nonantigen-dependent inflammatory pathways in transplantation. Transplantation 79(5):505–514
Langrehr JM, Gube K, Hammer MH, Lehmann M, Polenz D, Pascher A et al (2007) Short-term anti-CD4 plus anti-TNF-alpha receptor treatment in allogeneic small bowel transplantation results in long-term survival. Transplantation 84(5):639–646
van den Brande JM, Braat H, van den Brink GR, Versteeg HH, Bauer CA, Hoedemaeker I et al (2003) Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology 124(7):1774–1785
Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J (1995) Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 7(3):251–259
Chiang CH (2006) Effects of anti-tumor necrosis factor-alpha and anti-intercellular adhesion molecule-1 antibodies on ischemia/reperfusion lung injury. Chin J Physiol 49(5):266–274
Colletti LM, Remick DG, Burtch GD, Kunkel SL, Strieter RM, Campbell DA Jr (1990) Role of tumor necrosis factor-alpha in the pathophysiologic alterations after hepatic ischemia/reperfusion injury in the rat. J Clin Invest 85(6):1936–1943
Daemen MA, van de Ven MW, Heineman E, Buurman WA (1999) Involvement of endogenous interleukin-10 and tumor necrosis factor-alpha in renal ischemia-reperfusion injury. Transplantation 67(6):792–800
Gurevitch J, Frolkis I, Yuhas Y, Lifschitz-Mercer B, Berger E, Paz Y et al (1997) Anti-tumor necrosis factor-alpha improves myocardial recovery after ischemia and reperfusion. J Am Coll Cardiol 30(6):1554–1561
Ishii D, Schenk AD, Baba S, Fairchild RL (2010) Role of TNFalpha in early chemokine production and leukocyte infiltration into heart allografts. Am J Transplant 10(1):59–68
Inohara N, Chamaillard M, McDonald C, Nunez G (2005) NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu Rev Biochem 74:355–383
Janse M, Weersma RK, Sudan DL, Festen EA, Wijmenga C, Dijkstra G et al (2010) Association of Crohn’s disease-associated NOD2 variants with intestinal failure requiring small bowel transplantation and clinical outcomes. Gut 60(6):877–878
Ningappa M, Higgs BW, Weeks DE, Ashokkumar C, Duerr RH, Sun Q et al (2010) NOD2 gene polymorphism rs2066844 associates with need for combined liver–intestine transplantation in children with short-gut syndrome. Am J Gastroenterol 106(1):157–165
Wehkamp J, Stange EF (2010) Paneth’s disease. J Crohns Colitis 4(5):523–531
Conflicts of interest
None.
Funding sources
This study was supported by grants from Deutsche Forschungsgemeinschaft (KFO 115/1-1, Teilprojekt 3) and the BONFOR Program of the University of Bonn (O-112.0024, O-112.0013 and O-112.0015).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pech, T., Fujishiro, J., Finger, T. et al. Perioperative infliximab application has marginal effects on ischemia–reperfusion injury in experimental small bowel transplantation in rats. Langenbecks Arch Surg 397, 131–140 (2012). https://doi.org/10.1007/s00423-011-0853-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00423-011-0853-0